Why insider trading matters?
Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
- Peter Lynch
Why insider trading matters?
Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. It is also developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety.
Trade Date | Insider | Title | Buy/Sell | #Shares | Price | Value | Option |
---|---|---|---|---|---|---|---|
2021-01-11 | Durgam Suresh K. | Chief Medical Officer | Sell | 4,367 | $32.12 | $140,259 | Yes |
2021-01-11 | Neumann Mark | EVP, Chief Commercial Officer | Sell | 9,684 | $32.02 | $310,082 | Yes |
2021-01-11 | Hineline Lawrence J. | SVP of Finance CFO | Sell | 19,638 | $32.02 | $628,769 | Yes |
2021-01-11 | Halstead Michael | EVP and General Counsel | Sell | 19,638 | $32.03 | $628,978 | Yes |
2021-01-11 | Mates Sharon | Chairman, President & CEO | Sell | 41,896 | $32.01 | $1,341,260 | Yes |
2021-01-04 | Hineline Lawrence J. | SVP of Finance CFO | Sell | 15,810 | $31.31 | $495,008 | Yes |
2021-01-04 | Halstead Michael | EVP and General Counsel | Sell | 16,160 | $31.30 | $505,834 | Yes |
2021-01-04 | Mates Sharon | Chairman, President & CEO | Sell | 48,341 | $31.30 | $1,513,271 | Yes |
2020-11-17 | Halstead Michael | EVP and General Counsel | Sell | 79,425 | $27.62 | $2,193,446 | Yes |
2020-11-11 | Hineline Lawrence J. | SVP of Finance CFO | Sell | 28,034 | $25.41 | $712,344 | Yes |
2020-11-10 | Mates Sharon | Chairman, President & CEO | Sell | 50,000 | $26.34 | $1,317,101 | No |
2020-11-04 | Mates Sharon | Chairman, President & CEO | Sell | 50,000 | $25.00 | $1,250,000 | No |
2020-10-16 | Neumann Mark | EVP, Chief Commercial Officer | Sell | 6,792 | $26.80 | $182,026 | Yes |
2020-09-14 | Alafi Christopher D | Director | Buy | 49,500 | $29.60 | $1,465,200 | No |
2020-09-09 | Hineline Lawrence J. | SVP of Finance CFO | Sell | 41,983 | $31.14 | $1,307,351 | Yes |
2020-09-11 | Alafi Christopher D | Director | Buy | 21,000 | $28.08 | $589,680 | No |
2020-05-14 | MARCUS JOEL S | Director | Sell | 9,602 | $20.04 | $192,424 | No |
2020-05-13 | MARCUS JOEL S | Director | Sell | 57,297 | $20.04 | $1,148,037 | No |
2020-05-11 | LERNER RICHARD A | Director | Sell | 3,500 | $20.50 | $71,750 | Yes |
2020-01-09 | Satlin Andrew | EVP and Chief Medical Officer | Sell | 11,573 | $26.16 | $302,750 | Yes |
2020-01-09 | Mates Sharon | Chairman, President & CEO | Sell | 41,895 | $26.16 | $1,095,973 | No |
2020-01-09 | Halstead Michael | EVP and General Counsel | Sell | 19,638 | $26.16 | $513,730 | No |
2020-01-09 | Hineline Lawrence J. | SVP of Finance CFO | Sell | 19,638 | $26.16 | $513,730 | No |
2020-01-08 | Mates Sharon | Chairman, President & CEO | Sell | 45,598 | $30.28 | $1,380,880 | Yes |
2020-01-06 | Halstead Michael | EVP and General Counsel | Sell | 21,458 | $30.34 | $651,007 | Yes |
2020-01-06 | Hineline Lawrence J. | SVP of Finance CFO | Sell | 21,458 | $30.29 | $650,003 | Yes |
2020-01-02 | Halstead Michael | EVP and General Counsel | Sell | 7,807 | $32.43 | $253,214 | Yes |
2020-01-02 | Hineline Lawrence J. | SVP of Finance CFO | Sell | 7,807 | $32.43 | $253,165 | Yes |
2020-01-02 | Mates Sharon | Chairman, President & CEO | Sell | 17,478 | $32.45 | $567,230 | Yes |
2019-12-23 | Hineline Lawrence J. | SVP of Finance CFO | Sell | 15,032 | $25.50 | $383,316 | Yes |
Insider Smart
Insider Smart